阿斯利康于周二表示，该公司正与甲骨文合作，利用人工智能和真实世界数据来识别符合临床试验条件的患者并监测安全性信号等措施，以期改进这家制药公司的临床研究。
AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.
此次合作将把阿斯利康的药物开发专业知识与甲骨文的人工智能和医疗健康数据能力相结合，以支持患者匹配和研究。初期工作将重点关注癌症、心血管、呼吸系统、免疫学和罕见病，并且还可能支持严重疾病的早期诊断。首个项目将与总部位于阿拉伯联合酋长国的医疗健康企业M42合作，支持阿布扎比的高血压研究。
患者招募仍然是临床研究中最大的挑战之一，入组延迟往往会延长试验时间并增加开发成本。阿斯利康正寻求扩大其药物产品组合，目标是到2030年实现年收入超过800亿美元，并致力于解决药物开发中的行业瓶颈。
The collaboration will combine AstraZeneca's drug development expertise with Oracle's AI and healthcare data capabilities to support patient matching and research Initial work will focus on cancer, cardiovascular, respiratory, immunology and rare diseases, and could also support earlier diagnosis of serious diseases The first project will support hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42 Patient recruitment remains one of the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs AstraZeneca is seeking to expand its medicine portfolio as it targets over $80 billion in annual revenue by 2030, and works to address industry bottlenecks in drug development